Notably, clinical trials involving the application of the anti-CD52 antibody, alemtuzumab (NCT00069238, NCT00040846, and NCT00118352), in NKTCL are currently being conducted. This evidence concerns the gene CD52 and extranodal nasal NK/T cell lymphoma.